Impact of FDA power morcellation warning
Posted on Monday, January 9th, 2017 at 5:27 pm by Williams Hart | Updated: Thursday, March 7th, 2019 at 4:47 pm
In 2014, the US Food and Drug Administration (FDA) issued a warning about the potential risks of using laparoscopic power morcellators in hysterectomies or myomectomies. Since the announcement, there was a decrease in the utilization of minimally invasive hysterectomies, based on a retrospective cohort study conducted by the faculty from the University of Michigan Department of Obstetrics and Gynecology.
In the review, the utilization of power morcellators has significantly decreased, but cases in which a practitioner still opts to use major surgical non-transfusion, complications have increased by 27 percent and occurrences of 30-day hospital re-admissions have increased by 25 percent. Although the cause of the shift in practice patterns has yet to be determined, the study suggests that it has something to do with the FDA announcement discouraging the use of the medical device.
If you or someone you know has developed an undetected cancer following a hysterectomy or myomectomy involving a power morcellator, you may be entitled to a financial compensation. Our lawyers at Williams Hart have worked closely with these lawsuits and can properly represent you in court. Get in touch with us at (800) 220-9341 to learn more about your legal options.